Immucell corporation ICCC.US Value Analysis
)ICCC Value Score
3
24
15
- AI analysis rates ICCC with a medium value score of 3.
- It is mainly due to stable operating cash flow, but with concerns regarding potential value may be lower.
- Over the past 3 months, ICCC has maintained a consecutive value rating of 3.0, higher than the rating of 0.5 over the past 3 years, indicating noticeable improvement in enterprise value.
- Compared to all stocks in the Health Care sector, ICCC has a medium value rating.
ICCC Value Reference Factors
The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.
Update to 2025/03/22 (Weekly Update)
ICCC Financial Forecast
Unit : USD
Update to 2025/5/9 (Quarterly Update)
ICCC Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | 0.03 | - | 175% | 3.74M | - | -59.6% | -8.7% |
Update to 2025/5/10 (Quarterly Update)
ICCC Historical Value Score
You can use historical scores of 3 or above to observe potential performance and make investment decisions.
ICCC Value Strategy Backtest
The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.
The Backtest Result of ICCC from 2007/01 till Now
- 39.15%
- Cumulative Return
- 2.00%
- Annual Return
- 58.01%
- Volatility
- 0.03
- Sharpe Ratio
Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to May, 2025. (Total Trades: 4)
| ICCC | Sector | US Overall Market | |
|---|---|---|---|
| Wining Rate | 75% | 45% | 54% |
| Avg Return | 17.3% | 62.9% | 72.8% |
| Avg Profit | 40.1% | 197.1% | 165.9% |
| Avg Loss | -51.2% | -45.1% | -34.6% |
| Avg Risk-Reward Ratio | 78.4% | 437% | 479.2% |
Update to 2025/5/10 (Daily Update)